Gastrazole for Advanced Pancreatic Cancer
Author Information
Author(s): Chau I, Cunningham D, Russell C, Norman A R, Kurzawinski T, Harper P, Harrison P, Middleton G, Daniels F, Hickish T, Prendeville J, Ross P J, Theis B, Hull R, Walker M, Shankley N, Kalindjian B, Murray G, Gillbanks A, Black J
Primary Institution: Royal Marsden Hospital
Hypothesis
Does gastrazole improve survival in patients with advanced pancreatic cancer compared to placebo and fluorouracil?
Conclusion
Gastrazole appeared to improve survival compared to placebo but did not show a survival advantage over fluorouracil.
Supporting Evidence
- Gastrazole produced significantly better survival compared to placebo (median 7.9 months vs 4.5 months).
- No significant survival difference was detected between gastrazole and 5-FU (median: 3.6 vs 4.2 months).
- Toxicity of gastrazole was mild with significantly less diarrhoea, stomatitis, and hand-foot syndrome compared to 5-FU.
Takeaway
Gastrazole might help people with advanced pancreatic cancer live longer than those who get a placebo, but it doesn't work better than a common chemotherapy drug called fluorouracil.
Methodology
Two randomized controlled trials were conducted comparing gastrazole with placebo and fluorouracil in patients with advanced pancreatic cancer.
Potential Biases
Potential bias due to the small sample size and the nature of the trials.
Limitations
The sample size was small, and the trials were underpowered to detect significant differences in survival between gastrazole and fluorouracil.
Participant Demographics
Patients with biopsy-proven, inoperable pancreatic carcinoma, aged 18 or older.
Statistical Information
P-Value
0.02
Confidence Interval
95% CI: 7.8–62.3%
Statistical Significance
p=0.02
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website